Solange Peters

Overview

Best Publications

• Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network

  Eric A. Collisson;Joshua D. Campbell;Angela N. Brooks;Angela N. Brooks;Alice H. Berger

  5272
  Citations

• Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

  T.A. Chan;M. Yarchoan;E. Jaffee;C. Swanton

  2763
  Citations

• First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

  David P. Carbone;Martin Reck;Luis Paz-Ares;Benjamin Creelan

  2456
  Citations

• Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

  Solange Peters;D. Ross Camidge;Alice T. Shaw;Shirish Gadgeel

  2265
  Citations

• Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

  Matthew D Hellmann;Luis Paz-Ares;Reyes Bernabe Caro;Bogdan Zurawski

  2247
  Citations

• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  J. B. A. G. Haanen;F. Carbonnel;C. Robert;K. M. Kerr

  2173
  Citations

• Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.

  Filipe Martins;Filipe Martins;Latifyan Sofiya;Gerasimos P. Sykiotis;Faiza Lamine

  2122
  Citations

• Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

  Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  1776
  Citations

• Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  J. Vansteenkiste;D. De Ruysscher;W.E.E. Eberhardt;E. Lim

  1775
  Citations

• Quantifying the biodiversity value of tropical primary, secondary, and plantation forests.

  J. Barlow;T. A. Gardner;I. S. Araujo;T. C. Ávila-Pires

  1444
  Citations

• First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

  Paul Baas;Arnaud Scherpereel;Anna K Nowak;Nobukazu Fujimoto

  854
  Citations

• Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  M Reck;S Popat;N Reinmuth;Dirk De Ruysscher

  827
  Citations

• Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

  Julien Mazières;Solange Peters;Benoit Lepage;Alexis B. Cortot

  697
  Citations

• Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  M Früh;Dirk De Ruysscher;S Popat;L Crinò

  665
  Citations

• COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.

  Marina Chiara Garassino;Jennifer G. Whisenant;Li Ching Huang;Annalisa Trama

  597
  Citations

• Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

  Charles M Rudin;Mark M Awad;Alejandro Navarro;Maya Gottfried

  545
  Citations

• 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

  J. Vansteenkiste;L. Crinò;C. Dooms;J. Y. Douillard

  530
  Citations

• Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.

  T. Mok;D.R. Camidge;S.M. Gadgeel;R. Rosell

  508
  Citations

• Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

  Naiyer A Rizvi;Byoung Chul Cho;Niels Reinmuth;Ki Hyeong Lee

  505
  Citations

• EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.

  E. Le Rhun;M. Weller;D. Brandsma;M. Van den Bent

  497
  Citations